LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on IRON stock, giving a Buy rating on June 13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight the promising clinical potential of Disc Medicine’s pipeline. The updates presented at the EHA 2025 Annual Congress showcase the favorable long-term safety and efficacy of bitopertin in treating EPP, demonstrating sustained reductions in PPIX and improvements in quality of life measures for patients. Additionally, the reduction in ALT levels and other hepatobiliary biomarkers further underscore bitopertin’s potential as a disease-modifying treatment.
Moreover, the safety profile of bitopertin remains favorable, with most adverse events being mild or moderate in severity. The initiation of the APOLLO study, which aims to further evaluate the efficacy and safety of bitopertin, adds to the confidence in the company’s clinical strategy. These factors, combined with the company’s financial position, including a cash runway of 3.2 years, support the Buy rating for Disc Medicine’s stock.